Deya Corzo, MD
About Deya Corzo, MD
Deya Corzo, MD, serves as CMO-in-residence at Roivant Sciences and is a member of the Scientific Advisory Board at MiNA Therapeutics. With over 20 years of experience in clinical genetics and a background in leadership roles at various biopharmaceutical companies, she has made significant contributions to the field of rare and genetic therapeutics.
Current Role at Roivant Sciences
Deya Corzo serves as the Chief Medical Officer in Residence at Roivant Sciences since 2022. In this role, she contributes her expertise in clinical genetics and biotechnology to advance the company's initiatives. Roivant Sciences focuses on innovative approaches to drug development, and Corzo's experience in medical affairs and clinical research supports the organization's mission.
Previous Experience at Sigilon Therapeutics
Before her current position, Deya Corzo worked at Sigilon Therapeutics, Inc. as the Executive Vice President and Chief Medical Officer from 2018 to 2021. During her tenure in Cambridge, MA, she played a significant role in developing therapies aimed at treating rare diseases through innovative gene therapies.
Educational Background and Clinical Training
Deya Corzo obtained her medical degree from Universidad Industrial de Santander, completing her studies from 1984 to 1991. She furthered her education at Harvard Medical School, where she completed a Clinical Fellowship in Clinical Genetics at Boston Children's Hospital from 1998 to 2001. Additionally, she pursued a Research Fellowship in Immunogenetics at Dana Farber Cancer Institute from 1993 to 1995.
Contributions to Clinical Genetics
Deya Corzo has over 20 years of experience as an attending physician in Clinical Genetics at Boston Children's Hospital, where she has been instrumental in advancing the field. Her work has included pioneering advancements in rare and genetic therapeutics across various biopharmaceutical companies. She is recognized as a subject matter expert and has contributed to the education of future medical professionals as a faculty member at Harvard Medical School.
Advisory Role at MiNA Therapeutics
In addition to her role at Roivant Sciences, Deya Corzo serves on the Scientific Advisory Board of MiNA Therapeutics since 2022. In this capacity, she provides strategic insights and guidance on the development of RNA-based therapeutics, leveraging her extensive background in clinical research and medical affairs.